Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 25 a 50 de 345
Resumen de: US20260309720A1
This invention relates to the detection of Tau protein in body fluids using biomarker peptides and their detection by Multiplexed Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS) methods such as Selected Reaction Monitoring (SRM). In particular, the biomarker peptides are intended to distinguish between Tau protein produced by the Peripheral Nervous System and Tau protein produced by the Central Nervous System. This invention also relates to methods of using these peptide biomarkers for diagnosing and/or classifying the severity of a Neurodegenerative Disease, treatment of a Neurodegenerative Disease and assessing the efficacy of a treatment for a Neurodegenerative Disease, in particular for Tauopathies such as Alzheimer's disease. Also provided are a kit for diagnosing and/or classifying the severity of a Neurodegenerative disease, a kit for use in the treatment of a Neurodegenerative disease and a kit for assessing the efficacy of a treatment for a Neurodegenerative Disease in a subject.
Resumen de: US20260309725A1
The invention relates to a nasal fluid sample obtained from a subject comprising the marker protein(s) β amyloid (Aβ), phosphorylated Tau (pTau) and/or total Tau (tTau). The invention further relates to a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for use in a method for the aid in diagnosis of neurodegenerative diseases and the use of a nasal fluid sample comprising the marker protein(s) Aβ, pTau and/or tTau for the aid in diagnosis of a neurodegenerative disease. The invention further relates to a method for the aid in diagnosis of a neurodegenerative disease in a subject/individual.
Resumen de: US20260309712A1
Improved antibodies for detection of phosphorylated RBL1, H1.5, LARP6, SUV39H1, and FAM53C have been developed. Assays using them to detect the biomarkers: P-T143 FAM53C, P-T202 LARP6, P-S988 RBL1, P-S17 H1.5, and P-S391 SU-V39H1, and diagnostic and prognostic applications stemming therefrom are also provided.
Resumen de: US20260309715A1
0000 Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
Resumen de: US20260309705A1
Provided herein are methods for monitoring treatment for multiple sclerosis in a pregnant subject, and determining the efficacy of a treatment for multiple sclerosis in a pregnant subject. These methods include (a) extracting a drug from a dried blood spot (DBS) sample from a pregnant subject after a treatment for multiple sclerosis has been administered to the pregnant subject; (b) performing mass spectrometry on the extracted DBS sample; (c) determining a peak area ratio of the extracted DBS sample to an internal standard; and (d) identifying the administered treatment as being below the internal standard threshold if the plasma concentration of the treatment is less than 1 as compared to the internal standard ratio. Also provided herein are dried blood spot cards, and kits that include a dried blood spot card pre-treated with at least one internal standard.
Resumen de: US20260306596A1
0000 The present invention is directed inter alia to the treatment of pain. For example, there is provided a chimeric clostridial neurotoxin for use in treating pain by inhibiting the release of a pain mediator from a neuron comprising an Aδ nerve fiber or a C nerve fiber, wherein the chimeric clostridial neurotoxin binds to the neuron comprising the Aδ nerve fiber or the C nerve fiber, respectively, and wherein the chimeric clostridial neurotoxin comprises a botulinum neurotoxin A (BoNT/A) light-chain and translocation domain (H
Resumen de: EP4818330A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein rhereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: EP4818331A2
0001 The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.
Resumen de: WO2025059015A1
Described herein is a system comprising a eukaryotic cell, wherein the eukaryotic cell comprises: a plasma membrane polypeptide coupled to a transcription factor by a linker, wherein the linker comprises a protease cleavable site; and a plasma membrane anchored protease; wherein the plasma membrane anchored protease is capable of cleaving the linker. The system can further include a reporter construct, wherein the transcription factor can bind to a promoter of the reporter construct to indicate an ability of the plasma membrane polypeptide to traffic to the plasma membrane.
Resumen de: AU2019205489A1
This invention generally pertains to antibodies and antigen-binding fragments thereof, e.g., humanized, chimeric, and human antibodies and antigen-binding fragments thereof, and fusion proteins, compositions containing such antibodies and antigen-binding fragments thereof and fusion proteins, wherein such antibodies and antigen-binding fragments thereof and fusion proteins specifically bind to MCT1, e.g., human or non-human MCT1 and antagonize, inhibit or block one or more MCT1-associated functions
Resumen de: US20260298931A1
0000 A method for detecting colorectal cancer DNA using a lateral flow assay includes: extracting a blood sample (S100); loading the blood sample on a lateral flow assay (LFA) kit (S110); amplifying a specific target circulating tumor DNA (ctDNA) fragment using single nucleotide polymorphism (SNP) typing based on a loop-mediated isothermal amplification (LAMP) device on the kit (S130); allowing the amplified SNP sequence to move along a nitrocellulose membrane and binding to a gold nanoparticle probe to form a DNA-AuNP complex (S140); and color-developing a first probe to be visually detected in the complex forming process (S150), so as to detect whether colorectal cancer mutant DNA exists in the blood sample based on the color development.
Resumen de: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Resumen de: WO2026207317A1
A method for screening a subject in need thereof for amyotrophic lateral sclerosis (ALS) or slowing a progression of ALS, wherein the method includes measuring a level of at least a biomarker in the subject, such as without limitation by using a synthetic antibody, determining an ALS status indicator as a function of the measurement, and optionally providing a treatment to slow the progression of ALS as a function of the ALS status indicator, wherein the at least a biomarker includes a trimeric superoxide dismutase 1 (SOD1).
Resumen de: WO2026205616A1
The present invention relates to an anti-APP antibody or an antigen-binding fragment thereof, and uses thereof. Specifically, the anti-APP antibody or antigen-binding fragment thereof according to the present invention may be utilized for analysis and detection of cell membrane APP, and further for diagnosis of APP-related diseases.
Resumen de: WO2026202211A1
Methods of immunoassay are described for detecting in a patient sample (such as for example a blood, serum or plasma sample) a biomarker originating from α-Synuclein, and to the use of said methods of immunoassay for detecting and/or monitoring Parkinson's Disease or a level of severity thereof. Monoclonal antibodies and assay kits for use in said methods of immunoassay are also described.
Resumen de: WO2026207302A1
Compositions, kits, systems, and methods for determining the presence and/or concentration of a phosphorylated Tau biomarker (such as, but not limited to, pTau217) in a biological sample and/or determining the presence of, severity of, and/or predisposition to Alzheimer's disease in an individual are disclosed. The compositions, kits, systems, and methods utilize at least two means for binding to Tau, including one means that is capable of distinguishing the phosphorylated Tau biomarker from unphosphorylated Tau, so that at least one sandwich complex can be formed. The methods include determining an amount of pTau present in the biological sample based on the amount of the sandwich immunocomplex formed.
Resumen de: WO2026207251A1
The present disclosure provides systems, methods, compositions, and algorithms for treating a subject diagnosed with a glucose hypometabolic disorder (e.g., Alzheimer's disease, Parkinson's disease, or heart failure).
Resumen de: AU2024347751A1
The present invention provides various biomarkers for identifying patients that are likely to benefit from treatment with a TLR inhibitor.
Resumen de: US20260298947A1
0000 A method for the in vitro diagnosis of a neurodegenerative disease, in a human or animal individual, at an early stage, including the step which includes in detecting the presence of at least one marker chosen from the derived forms of amyloid beta (Aβ) peptides selected from the oligomers of said peptides and the prefibrillar and fibrillar aggregated forms of said peptides, and the derived forms of phosphorylated tau proteins selected from the hyperphosphorylated forms of said proteins, the aggregated forms of said proteins and the modified phosphorylated tau proteins resulting from one or several post-translational modifications, the presence of the marker(s) being detected in a stool sample of said individual.
Resumen de: US20260298958A1
Disclosed is a specimen analysis method for analyzing a specimen regarding a plurality of measurement items, the specimen analysis method comprising: measuring a first measurement item and a second measurement item on the basis of a measurement order; executing a process related to a time difference between a measurement of the first measurement item and a measurement of the second measurement item; and obtaining a calculation value from a measurement value of the first measurement item and a measurement value of the second measurement item.
Resumen de: US20260294329A1
0000 A non-invasive device for detecting Alzheimer's Disease-associated pathologies, comprising a fundus camera comprising a spectral reflectance imaging unit that includes a broadband light source and a light sensor and a lens assembly to focus light from the broadband light source onto a fundus of an eye, and one or more processors to detect reflected and/or backscattered light from the eye, illuminated by the broadband light source, using the light sensor for determining spectral reflectance information, generate a plurality of spectral reflectance maps comprising counts of reflected and/or backscattered light at a different wavelength or a different range of wavelengths, assign a weight to each of the spectral reflectance maps, and determine one or more regions of interest from the weighted spectral reflectance maps as being a potential Alzheimer's Disease-associated pathology based on a detection of one or more biomarkers indicative of Tauopathy.
Resumen de: US20260297180A1
0000 The present invention relates to the field of inflammation. More specifically, the present invention provides compositions and methods for treating diseases and conditions associated with the priming and activation of the NLR Family Pyrin Domain Containing 3 (NLRP3) inflammasome. In particular embodiments, the method comprises the step of administering to the patient an isolated, recombinant antibody or antigen-binding fragment thereof that binds human Resistin.
Resumen de: US20260298946A1
The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.
Resumen de: US20260297486A1
0000 Disclosed herein are 3D culture systems and methods for producing epithelial tubular organoids, such as intestinal organoids. Also disclosed is a screening method that involves contacting elongated epithelial tubes produced from the disclosed systems and methods with a candidate agent, culturing the elongated epithelial tube in a growth medium under growth conditions, and evaluating the elongated epithelial tube for a physiological effect.
Nº publicación: US20260297525A1 01/10/2026
Solicitante:
NEW YORK BLOOD CENTER INC [US]
New York Blood Center, Inc.
Resumen de: US20260297525A1
Disclosed herein are methods of expanding populations of patrolling monocytes in vitro and in vivo for treatment of sickle-cell disease (SCD), reducing pain and vaso-occlusive events in SCD patients, promoting wound healing, reducing tumor metastases, and treating vascular inflammatory conditions in subjects in need thereof.
BOPI
Sede Electrónica
